BioLineRx Ltd. (BLRX)
| Market Cap | 12.49M |
| Revenue (ttm) | 12.74M |
| Net Income (ttm) | -2.98M |
| Shares Out | 2.61B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,234 |
| Open | 2.740 |
| Previous Close | 2.880 |
| Day's Range | 2.740 - 2.900 |
| 52-Week Range | 2.300 - 7.770 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+571.38%) |
| Earnings Date | Mar 30, 2026 |
About BLRX
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les... [Read more]
Financial Performance
In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 571.38% from the latest price.
News
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
BioLineRx Ltd. ( BLRX) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial ...
BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall
BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall
BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture
BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture
BioLineRx GAAP EPS of $0.00 beats by $0.54, revenue of $0.43M misses by $0.24M
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial ...
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ: LOT) is likely to report earnings for its third quarter. • Qudian (NYSE: QD) is estimated to report earnings for its third quarter. • ...
BioLine Rx's Earnings: A Preview
BioLine Rx (NASDAQ: BLRX) is gearing up to announce its quarterly earnings on Monday, 2025-11-24. Here's a quick overview of what investors should know before the release. Analysts are estimating tha...
BioLineRx Q3 2025 Earnings Preview
BioLineRx (BLRX) is scheduled to announce Q3 earnings results on Monday, November 24th, before market open. The consensus EPS Estimate is -$0.54 (-Infinity% Y/Y) and the consensus
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent prot...
BioLineRx Ltd. (BLRX) Investor Call (Transcript)
BioLineRx and Hemispherian launch a joint venture to develop GLIX1, a first-in-class
BioLineRx Ltd. - Special Call
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblas...
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash...
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE: STG) is likely to report earnings for its second quarter. • TORM (NASDAQ: TRMD) is expected to report quarterly earnings at $0.57 per...
BioLineRx Q2 2025 Earnings Preview
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 Am...
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd’s (NASDAQ: BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at ...
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31 st TEL AVIV, Israel , May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDA...